Sudafed XyloSpray HA for Children, 0.5 mg/ml, Nasal Spray, Solution
Xylometazoline Hydrochloride
This medicine should always be used exactly as described in this package leaflet for the patient or as directed by a doctor or pharmacist.
Sudafed XyloSpray HA for Children contains xylometazoline, which helps to constrict blood vessels inside the nasal cavity, reducing swelling of the nasal mucosa and making it easier to breathe. Sudafed XyloSpray HA for Children also contains hyaluronic acid (in the form of sodium salt), which protects and moisturizes the nasal mucosa.
The spray is used for the short-term treatment of nasal congestion with a runny nose, occurring in the course of a cold or sinusitis.
This medicine is not intended for children under 2 years of age.
Before starting to use the medicine, the patient should discuss it with their doctor or pharmacist in the following cases:
Continuous useof the medicine for a long period may cause worsening of nasal congestion symptoms.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
DO NOTtake the medicine while using:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
The medicine should not be used during pregnancy due to the lack of data on its effects on the fetus.
Breastfeeding women should consult their doctor before using the medicine.
It is not known whether the active substance of this medicine passes into breast milk.
No effects of Sudafed XyloSpray HA for Children on the ability to drive and use machines have been observed.
This medicine should always be used exactly as described in this package leaflet for the patient or as directed by a doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist.
Unless otherwise directed by a doctor or pharmacist, one dose of Sudafed XyloSpray HA for Children should be used in each nostril, up to 3 times a day, not longer than for 5-7 days.The recommended dose should not be exceeded.
To minimize the risk of spreading infections, the medicine packaging should not be used by more than one person, and the applicator should be rinsed after each use.
DO NOTuse the medicine in children under 2 years of age.
The patient should immediately contact their doctor, pharmacist, or the nearest emergency department, taking the medicine packaging or this package leaflet with them.
Using a higher dose of the medicine than recommended may cause central nervous system depression, e.g., loss of muscle function, fatigue, dry mouth, sweating, rapid and irregular heartbeat, and increased blood pressure.
If a dose of the medicine is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should not be taken, and the patient should continue using the medicine as directed. A double dose should not be taken to make up for a missed dose.
If the patient has any further doubts about using this medicine, they should consult their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP USINGthe medicine IMMEDIATELY AND CONSULTa doctor if any of the following side effects occur, which may be symptoms of an allergic reaction:
Reporting side effects
If side effects occur, including any not listed in this package leaflet, the patient should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Medicines Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Store at a temperature below 25°C.
The shelf life of Sudafed XyloSpray HA for Children after opening the bottle: 1 year.
DO NOTuse Sudafed XyloSpray HA for Children after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substanceis xylometazoline hydrochloride. 1 ml of the solution contains 0.5 mg of xylometazoline hydrochloride. Each dose (70 μl) of Sudafed XyloSpray HA for Children contains 35 μg (or 0.035 mg) of xylometazoline hydrochloride.
Other ingredientsare: sodium hyaluronate, sorbitol (E420), glycerol (E422), sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, water for injections.
The spray is a clear to slightly opalescent, colorless to slightly yellowish solution, in a 10 ml white HDPE bottle with a dosing pump and a protective cap made of HDPE, in a cardboard box. The solution is sufficient for 110 doses.
McNeil Healthcare (Ireland) Limited
Office 5, 6 & 7, Block 5
High Street, Tallaght
Dublin 24, D24 YK8N
Ireland
Famar Health Care Services Madrid, S.A.U.
Avda. Leganés, 62
Alcorcón
28923 Madrid
Spain
Ursapharm Arzneimittel GmbH
Industriestraße 35
66129 Saarbrücken
Germany
Latvia
Olynth HA 0.5 mg/ml deguna aerosols bez konservantiem, šķīdums
Poland
Sudafed XyloSpray HA for Children
To obtain more detailed information, please contact:
email: consumer-pl@kenvue.com
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.